文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-PSMA PET/CT与18F-NaF PET/CT在新诊断高危前列腺癌160例患者骨转移评估中的前瞻性头对头比较

Prospective Head-to-Head Comparison of 18F-PSMA PET/CT and 18F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-02-03

这项前瞻性研究纳入160例组织学确诊的高危前列腺癌患者,均行18F-NaF PET/CT并在3周内行18F-PSMA PET/CT,由2名不知晓另一模态结果的核医学医师阅片。患者层面18F-PSMA PET/CT灵敏度0.98、特异度0.99、准确率0.99,18F-NaF PET/CT分别为0.91、1.00、0.97,无显著差异;两模态在154例(96.3%)患者中骨转移结论一致。18F-PSMA PET/CT倾向于检出更多骨转移灶;若18F-PSMA PET/CT未见骨转移,后续18F-NaF PET/CT可能冗余。

要点

  • 患者层面18F-PSMA PET/CT灵敏度0.98、特异度0.99、准确率0.99,18F-NaF PET/CT分别为0.91、1.00、0.97,无显著差异
  • 两模态患者层面骨转移一致率为154/160(96.3%)
  • 18F-PSMA PET/CT倾向于比18F-NaF PET/CT检出更多骨转移灶

核心结论

  • 18F-NaF与18F-PSMA PET/CT在新诊断高危前列腺癌患者中检测骨转移均具有高诊断准确率。
  • 18F-PSMA PET/CT可能较18F-NaF PET/CT检出额外转移灶。
  • 若18F-PSMA PET/CT未见骨转移,后续18F-NaF PET/CT可能冗余。

研究设计与样本

  • 前瞻性研究,纳入组织学确诊的高危前列腺癌患者,均由泌尿外科转诊行18F-NaF PET/CT,并在3周内行18F-PSMA PET/CT。
  • 图像由2名不知晓另一影像模态结果的核医学医师阅片,记录骨转移有无及转移灶数目。
  • 以患者层面两模态结果一致作为参考标准:一致时两模态均判为正确,不一致时追加随访扫描。
  • 共纳入160例参与者,计算灵敏度、特异度与准确率。

主要发现

  • 患者层面检测骨转移:18F-PSMA PET/CT灵敏度0.98、特异度0.99、准确率0.99;18F-NaF PET/CT灵敏度0.91、特异度1.00、准确率0.97;无显著差异。
  • 患者层面18F-NaF与18F-PSMA PET/CT骨转移一致率为154例(96.3%)。
  • 18F-PSMA PET/CT倾向于比18F-NaF PET/CT检出每例患者更多的骨转移灶。

关键数值与推荐

  • 患者层面18F-PSMA PET/CT检测骨转移:灵敏度0.98、特异度0.99、准确率0.99。
  • 患者层面18F-NaF PET/CT检测骨转移:灵敏度0.91、特异度1.00、准确率0.97。
  • 患者层面两模态骨转移一致率:154/160(96.3%)。

临床怎么用

  • 原文结论指出,若18F-PSMA PET/CT未见骨转移,后续18F-NaF PET/CT可能冗余。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used for primary staging in prostate cancer (PC), mainly because of its improved accuracy in detecting lymph node metastases compared with conventional imaging. However, the diagnostic benefit of PSMA PET/CT for detecting bone metastases is less well established. This study compares the diagnostic accuracy of 18F-PSMA PET/CT and 18F-NaF PET/CT for detecting bone metastases in patients newly diagnosed with PC. Methods: This prospective study included patients with histologically confirmed high-risk PC. All participants were referred from the department of urology to 18F-NaF PET/CT and underwent 18F-PSMA PET/CT within 3 weeks. Images were reviewed by 2 nuclear medicine physicians unaware of the results of the other imaging modality. Presence or absence of bone metastases and number of metastatic lesions were recorded. A reference standard was established at the patient level based on agreement between the 2 imaging modalities. In cases of concordance, both modalities were deemed correct. In cases of discordance, additional follow-up scans were performed. Diagnostic performance metrics, including sensitivity, specificity, and accuracy, were calculated. Results: In total, 160 participants were included. Sensitivity, specificity, and accuracy for detecting bone metastases at the patient level were 0.98, 0.99, and 0.99, respectively, for 18F-PSMA PET/CT, and 0.91, 1.00, and 0.97, respectively, for 18F-NaF PET/CT. No significant differences were found. The concordance rate of bone metastases between 18F-NaF and 18F-PSMA PET/CT at the patient level was observed in 154 patients (96.3%). 18F-PSMA PET/CT tended to identify more bone metastases per patient than 18F-NaF PET/CT. Conclusion: Both 18F-NaF and 18F-PSMA PET/CT exhibit high diagnostic accuracy for detecting bone metastases in newly diagnosed high-risk PC patients. 18F-PSMA PET/CT may detect additional metastatic lesions compared with 18F-NaF PET/CT. Subsequent 18F-NaF PET/CT may be redundant if no bone metastases are found on 18F-PSMA PET/CT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Madsen C, Fuglø D, Pedersen M, et al. Prospective Head-to-Head Comparison of 18F-PSMA PET/CT and 18F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer. J Nucl Med. 2025. PMID: 39778967. doi:10.2967/jnumed.124.268275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。